This Stock Just Made a Historical Debut on the Exchanges

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  
  • Home
  • Views On News
  • Nov 15, 2021 - This Stock Just Made a Historical Debut on the Exchanges

This Stock Just Made a Historical Debut on the Exchanges

Nov 15, 2021

This Stock Just Made a Historical Debut on the Exchanges

Shares of Sigachi Industries made a historical debut at the bourses today as the company listed at Rs 575 on the BSE, a 252.8% premium over the issue price of Rs 163. The stock listed at Rs 570 on the NSE at a premium of 250%.

Just a day before listing, the stock was commanding a premium of Rs 220-230 in the grey market, hinting towards a robust debut on the exchanges.

Minutes after the blockbuster debut, the shares rose to a new high of Rs 603.8 apiece, a premium of 270%.

What does Sigachi Industries do?

Hyderabad-based Sigachi Industries manufactures microcrystalline cellulose (MCC), which has varied applications in the pharmaceutical, food, nutraceuticals and cosmetic industries.

The company initially started its journey manufacturing chlorinated paraffin and hydrochloric acid in its manufacturing unit situated at Hyderabad.

--- Advertisement ---
Rahul Shah's Lazy Millionaire Summit Is Now LIVE...

Discover the Master Key to Turning Every Market Crash to Your Advantage

Hurry up! Join in now...

Click Here to Join the Lazy Millionaire Summit
------------------------------

The company then diversified its product portfolio to manufacture microcrystalline cellulose (MCC). MCC is widely used as an excipient for finished dosages in the pharmaceutical industry.

The major grades of MCC manufactured and marketed by the company are branded as HiCel and AceCel.

Issue oversubscribed by both retail and institutional investors

The issue opened for bidding on 1 November 2021 and closed on 3 November 2021, along Policybazaar and SJS Enterprises.

The price band of the initial public offering (IPO) was fixed at Rs 161-163 per share.

The offer comprised a fresh issue of 7.7 m equity shares aggregating up to Rs 1.3 bn at the upper price band of Rs 163. At the lower prices band of Rs 161, the issue was worth Rs 1.2 bn.

The IPO received a hefty response from investors as it was subscribed about 102 times. The quota for qualified institutional buyers was subscribed 86.5 times, whereas the quota for retail buyers was subscribed 80.5 times.

The portion for HNI investors was subscribed 172.4 times.

Equitymaster's Stock Screener: Identifying High-Potential Stocks Has Never Been this Easy

What does it plan to use the proceeds for?

The purpose of the issue is to fund capital expenditure for expansion of production capacity for MCC at its Dahej and Jhagadia plants and to manufacture Croscarmellose Sodium at the Kurnool plant.

It will also use the proceeds for general corporate purposes.

The commercial success of the company is largely dependent upon its ability to develop and devise innovative grades of cellulose based excipients.

Its inability to innovate new products would make its existing product portfolio redundant, which may have an adverse impact on the utility of products resultantly impacting revenue and profitability.

--- Advertisement ---
There is a new paradigm shift currently unfolding across the global economic landscape...

And at the heart of this massive SHIFT is...

INDIA!

India is on the verge of a multi-trillion-dollar rebirth that could potentially mint countless new millionaires...

If you are on the right side of this mega shift, then it could be your biggest opportunity to build potentially massive wealth over the long term.

Click here to find all the details...
------------------------------

Should you invest in an IPO for listing gains?

Amid the ongoing IPO fever, people are increasingly looking to try and make quick and appealing returns by putting their money in the shares of a company going public.

The idea here is to make listing gains through the purchase and sale of shares in a public issue.

However, there is no guarantee that a stock will always open at a gain.

This is completely dependent on the demand for the IPO, market sentiment, global factors and short-term outlook, among other things.

Hence, it would be wise to invest in companies with longer horizons.

The companies should have solid fundamentals and good long-term growth prospects. One must also understand the business of the company along with the risks involved in investing.

To know what's moving the Indian stock markets today, check out the most recent share market updates here.

Disclaimer: This article is for information purposes only. It is not a stock recommendation and should not be treated as such. Learn more about our recommendation services here...

Ayesha Shetty

Ayesha Shetty is a financial writer with the StockSelect team at Equitymaster. An engineer by qualification, she uses her analytical skills to decode the latest developments in financial markets. This reflects in her well-researched and insightful articles. When she is not busy separating financial fact from fiction, she can be found reading about new trends in technology and international politics.

Equitymaster requests your view! Post a comment on "This Stock Just Made a Historical Debut on the Exchanges". Click here!

  

More Views on News

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Krsnaa Diagnostics IPO Opens Tomorrow: Key Points to Consider (Views On News)

Aug 3, 2021

Krsnaa Diagnostics grey market premium is at around Rs 440 from its issue price of Rs 933-954.

Windlas Biotech IPO to Hit the Market on 4 August. Key Points to Know (Views On News)

Jul 31, 2021

Windlas Biotech IPO to open for subscription next week. Price band fixed at Rs 448-460.

More Views on News

Most Popular

Differences Between Trading and Investing

A simple to guide to understand the difference between investing and trading

Tata Steel vs SAIL: Which Stock is Better? (Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

Watch Out for these 4 Indian Companies Betting Big on EV Supply Chain (Views On News)

Jan 11, 2022

The upside in supply chain players could be huge but a delay in the transition to EVs, or any policy related hiccups could end the momentum.

These 5 Penny Stocks are Held by Rakesh Jhunjhunwala. Worth a Look? (Views On News)

Jan 18, 2022

Rakesh Jhunjhunwala is holding these penny stocks in his portfolio for several years now.

Tech Mahindra's CTC Acquisition: Too Expensive? (Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Jan 24, 2022 (Close)

MARKET STATS